ProCE Banner Activity

HUDSON: Open-Label, Multidrug Umbrella Phase II Study in Patients With Advanced NSCLC After Progression on PD-1/PD-L1 Inhibitor Therapy

Slideset Download
Conference Coverage
Results from the ongoing HUDSON study showed promising activity of durvalumab plus ceralasertib in both biomarker matched and nonmatched patients with locally advanced/metastatic NSCLC following platinum-doublet therapy and progression on PD-1/PD-L1 targeted immunotherapy.

Released: August 18, 2022

Expiration: August 17, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc